N/A N=70 Field Usability Study of Eclipse Mask
Obstructive Sleep Apnea
Primary: Number of Participants Who Asked for Additional Information — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=16,349 To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
SARS-CoV-2 Infection · COVID-19
Primary: SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim…
N/A N=173 Sleep Apnea Study in Adults Using DreamPort-Eclipse and a Traditional Nasal Mask
Obstructive Sleep Apnea
Primary: Apnea-Hypopnea Index (AHI) — 2.7; 2.5 events/h
Phase 2 N=80 Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
Cough · Idiopathic Pulmonary Fibrosis
Primary: Mean Change From Baseline in Weekly Average of the Daily Idiopathic Pulmonary Fibrosis Coughing Severity Scale (IPF CSS) — -0.69; -0.66; -0.26; -0.85 Points — p=0.989
N/A N=802 Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI
Prostate Cancer
Primary: Difference in Detection of Gleason Grade Group 2 or Higher Cancers Using Microultrasonography Plus Systematic Biopsy vs mpMRI/Conventional Ultrasonography Plus…
N/A N=107 AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid
Thyroid Nodules · Thyroid Cancer
Primary: Proportion of Eligible Patients for Feasibility — 213; 318 Participants
Phase 2 N=110 A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
Sleep Disturbances Associated With Menopause
Primary: Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG) — -23.50; -1.01 Minutes
N/A N=70 The Urinary Incontinence Treatment Study
Urinary Incontinence · Sarcopenia
Primary: Number of Urinary Incontinence Episodes — 4.3; 2.7 number of incontinence episodes
Phase 3 N=4 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Anaemia
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants
N/A N=63 Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment
Opioid Medication Assisted Treatment
Primary: Number of Patients Within Participating Sites With OUD Initiating MOUD During the Implementation Facilitation Period in Implementation Sites. This Will be Compared to…
N/A N=35 Simulated In-House Usability Study of Eclipse Continuous Positive Airway Pressure (CPAP) Device
Obstructive Sleep Apnea
Primary: Time to Complete Each Setup — 72.9; 14.6 seconds
N/A N=742,670 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
Diabetes
Primary: Time to Dementia Onset — 4.40; 6.06; 4.69; 6.71 Incidence rate per 1000 person year
Phase 2 N=144 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
N/A N=207 Group ("Project Life Force") vs. Individual Suicide Safety Planning RCT
Suicide
Primary: Columbia Suicide Rating Scale (C-SSRS) — 22; 30 participants with an event — p=0.263
Phase 4 N=92 Diltiazem in the Treatment of Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Rate
Atrial Fibrillation With Rapid Ventricular Response · Hypotension Drug-Induced
Primary: Mean Difference in Systolic Blood Pressure — -11.7500; -19.5385 mmHg